-
1
-
-
0004155654
-
-
4th edn. CRC Press, New York
-
Levine MM, Dougan G, Good MF, Liu MA, Nabel GJ, Nataro JP, Rappuoli R (eds) (2009) New generation vaccines, 4th edn. CRC Press, New York
-
(2009)
New Generation Vaccines
-
-
Levine, M.M.1
Dougan, G.2
Good, M.F.3
Liu, M.A.4
Nabel, G.J.5
Nataro, J.P.6
Rappuoli, R.7
-
2
-
-
0032077973
-
A simplified vaccinologists’ vaccinology and the pursuit of a vaccine against AIDS
-
Hilleman MR (1998) A simplified vaccinologists’ vaccinology and the pursuit of a vaccine against AIDS. Vaccine 16(8):778–793
-
(1998)
Vaccine
, vol.16
, Issue.8
, pp. 778-793
-
-
Hilleman, M.R.1
-
3
-
-
84929251318
-
Vaccinology in the era of high-throughput biology
-
Nakaya HI, Pulendran B (2015) Vaccinology in the era of high-throughput biology. Phil Trans R Soc Lond B Biol Sci 370. pii: 20140146. doi:10.1098/rstb.2014.0146
-
(2015)
Phil Trans R Soc Lond B Biol Sci
, vol.370
-
-
Nakaya, H.I.1
Pulendran, B.2
-
4
-
-
84954553168
-
Broadly neutralizing antibodies against HIV: New insights to inform vaccine design
-
Sadanand S, Suscovich TJ, Alter G (2016) Broadly neutralizing antibodies against HIV: new insights to inform vaccine design. Annu Rev Med 67:185–200. doi:10.1146/annurev-med-091014-090749
-
(2016)
Annu Rev Med
, vol.67
, pp. 185-200
-
-
Sadanand, S.1
Suscovich, T.J.2
Alter, G.3
-
5
-
-
84938603864
-
Hepatitis C virus: Why do we need a vaccine to prevent a curable persistent infection?
-
Walker CM, Grakoui A (2015) Hepatitis C virus: why do we need a vaccine to prevent a curable persistent infection? Curr Opin Immunol 35:137–143. doi:10.1016/j.coi.2015.06.010
-
(2015)
Curr Opin Immunol
, vol.35
, pp. 137-143
-
-
Walker, C.M.1
Grakoui, A.2
-
6
-
-
84960372950
-
Vaccines for established cancer: Overcoming the challenges posed by immune evasion
-
van der Burg SH, Arens R, Ossendorp F et al (2016) Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer 16:219–233. doi:10.1038/nrc.2016.16
-
(2016)
Nat Rev Cancer
, vol.16
, pp. 219-233
-
-
Van Der Burg, S.H.1
Arens, R.2
Ossendorp, F.3
-
7
-
-
84963631903
-
Systems analysis of immunity to influenza vaccination across multiple years and in diverse populations reveals shared molecular signatures
-
Nakaya HI, Hagan T, Duraisingham SS et al (2015) Systems analysis of immunity to influenza vaccination across multiple years and in diverse populations reveals shared molecular signatures. Immunity 43:1186–1198. doi:10.1016/j.immuni.2015.11.012
-
(2015)
Immunity
, vol.43
, pp. 1186-1198
-
-
Nakaya, H.I.1
Hagan, T.2
Duraisingham, S.S.3
-
8
-
-
84929598198
-
Decoding viral infection by ribosome profiling
-
Stern-Ginossar N (2015) Decoding viral infection by ribosome profiling. J Virol 89:6164–6166. doi:10.1128/JVI.02528-14
-
(2015)
J Virol
, vol.89
, pp. 6164-6166
-
-
Stern-Ginossar, N.1
-
9
-
-
84928770388
-
Neoantigens in cancer immunotherapy
-
Schumacher TN, Schreiber RD (2015) Neoantigens in cancer immunotherapy. Science 348:69–74. doi:10.1126/science.aaa4971
-
(2015)
Science
, vol.348
, pp. 69-74
-
-
Schumacher, T.N.1
Schreiber, R.D.2
-
10
-
-
33750862932
-
Vaccine manufacturing: Challenges and solutions
-
Ulmer JB, Valley U, Rappuoli R (2006) Vaccine manufacturing: challenges and solutions. Nat Biotechnol 24(11):1377–1383
-
(2006)
Nat Biotechnol
, vol.24
, Issue.11
, pp. 1377-1383
-
-
Ulmer, J.B.1
Valley, U.2
Rappuoli, R.3
-
11
-
-
84855810504
-
Discovery of T cell antigens by high-throughput screening of synthetic minigene libraries
-
Hondowicz BD, Schwedhelm KV, Kas A et al (2012) Discovery of T cell antigens by high-throughput screening of synthetic minigene libraries. PLoS One 7(1):e29949
-
(2012)
Plos One
, vol.7
, Issue.1
-
-
Hondowicz, B.D.1
Schwedhelm, K.V.2
Kas, A.3
-
12
-
-
3442896311
-
Messenger RNA-based vaccines
-
Pascolo S (2004) Messenger RNA-based vaccines. Expert Opin Biol Ther 4:1285–1294
-
(2004)
Expert Opin Biol Ther
, vol.4
, pp. 1285-1294
-
-
Pascolo, S.1
-
13
-
-
84921384147
-
The messenger’s great message for vaccination
-
Pascolo S (2015) The messenger’s great message for vaccination. Expert Rev Vaccines 14:153–156. doi:10.1586/14760584.2015.1000871
-
(2015)
Expert Rev Vaccines
, vol.14
, pp. 153-156
-
-
Pascolo, S.1
-
14
-
-
84921794613
-
MRNA-based therapeutics--developing a new class of drugs
-
Sahin U, Karikó K, Türeci Ö (2014) mRNA-based therapeutics--developing a new class of drugs. Nat Rev Drug Discov 13:759–780. doi:10.1038/nrd4278
-
(2014)
Nat Rev Drug Discov
, vol.13
, pp. 759-780
-
-
Sahin, U.1
Karikó, K.2
Türeci, Ö.3
-
15
-
-
84921508727
-
Vaccines “on demand”: Science fiction or a future reality
-
Ulmer JB, Mansoura MK, Geall AJ (2015) Vaccines “on demand”: science fiction or a future reality. Expert Opin Drug Discov 10:101–106. doi:10.1517/17460441.2015.996128
-
(2015)
Expert Opin Drug Discov
, vol.10
, pp. 101-106
-
-
Ulmer, J.B.1
Mansoura, M.K.2
Geall, A.J.3
-
16
-
-
84885730496
-
Messenger RNA-based vaccines: Progress, challenges, applications
-
Kramps T, Probst J (2013) Messenger RNA-based vaccines: progress, challenges, applications. Wiley Interdiscip Rev RNA 4:737–749. doi:10.1002/wrna.1189
-
(2013)
Wiley Interdiscip Rev RNA
, vol.4
, pp. 737-749
-
-
Kramps, T.1
Probst, J.2
-
17
-
-
84938827008
-
Modified mRNA as an alternative to plasmid DNA (PDNA) for transcript replacement and vaccination therapy
-
Youn H, Chung J-K (2015) Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy. Expert Opin Biol Ther 15:1337–1348. doi:10.1517/14712598.2015.1057563
-
(2015)
Expert Opin Biol Ther
, vol.15
, pp. 1337-1348
-
-
Youn, H.1
Chung, J.-K.2
-
18
-
-
0025231388
-
Direct gene transfer into mouse muscle in vivo
-
Wolff JA, Malone RW, Williams P et al (1990) Direct gene transfer into mouse muscle in vivo. Science 247:1465–1468
-
(1990)
Science
, vol.247
, pp. 1465-1468
-
-
Wolff, J.A.1
Malone, R.W.2
Williams, P.3
-
19
-
-
0032747388
-
DNA and RNA-based vaccines: Principles, progress and prospects
-
Leitner WW, Ying H, Restifo NP (1999) DNA and RNA-based vaccines: principles, progress and prospects. Vaccine 18:765–777. doi:10.1016/S0264-410X(99)00271-6
-
(1999)
Vaccine
, vol.18
, pp. 765-777
-
-
Leitner, W.W.1
Ying, H.2
Restifo, N.P.3
-
20
-
-
44949195901
-
Results of the first phase I/II clinical vaccination trial with direct injection of mRNA
-
Weide B, Carralot J-P, Reese A et al (2008) Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother 31(2):180–188
-
(2008)
J Immunother
, vol.31
, Issue.2
, pp. 180-188
-
-
Weide, B.1
Carralot, J.-P.2
Reese, A.3
-
21
-
-
79955630363
-
Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients
-
Rittig SM, Haentschel M, Weimer KJ et al (2011) Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther 19(5):990–999
-
(2011)
Mol Ther
, vol.19
, Issue.5
, pp. 990-999
-
-
Rittig, S.M.1
Haentschel, M.2
Weimer, K.J.3
-
22
-
-
84939463741
-
Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond: Recombinant mRNA technology and its application
-
Vallazza B, Petri S, Poleganov MA et al (2015) Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond: Recombinant mRNA technology and its application. Wiley Interdiscip Rev RNA. doi:10.1002/wrna.1288
-
(2015)
Wiley Interdiscip Rev RNA
-
-
Vallazza, B.1
Petri, S.2
Poleganov, M.A.3
-
23
-
-
84874724470
-
MRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic
-
Van Lint S, Heirman C, Thielemans K, Breckpot K (2013) mRNA: from a chemical blueprint for protein production to an off-the-shelf therapeutic. Hum Vaccin Immunother 9(2):265–274
-
(2013)
Hum Vaccin Immunother
, vol.9
, Issue.2
, pp. 265-274
-
-
Van Lint, S.1
Heirman, C.2
Thielemans, K.3
Breckpot, K.4
-
24
-
-
0033999511
-
Induction of anti-tumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA
-
Granstein RD, Ding W, Ozawa H (2000) Induction of anti-tumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA. J Invest Dermatol 114(4):632–636
-
(2000)
J Invest Dermatol
, vol.114
, Issue.4
, pp. 632-636
-
-
Granstein, R.D.1
Ding, W.2
Ozawa, H.3
-
25
-
-
0029839058
-
Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
-
Boczkowski D, Nair SK, Snyder D, Gilboa E (1996) Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184(2):465–472
-
(1996)
J Exp Med
, vol.184
, Issue.2
, pp. 465-472
-
-
Boczkowski, D.1
Nair, S.K.2
Snyder, D.3
Gilboa, E.4
-
26
-
-
77949440365
-
RNA as performance-enhancers for dendritic cells
-
Boczkowski D, Nair S (2010) RNA as performance-enhancers for dendritic cells. Expert Opin Biol Ther 10:563–574. doi:10.1517/14712591003614749
-
(2010)
Expert Opin Biol Ther
, vol.10
, pp. 563-574
-
-
Boczkowski, D.1
Nair, S.2
-
27
-
-
84870869040
-
Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection
-
Petsch B, Schnee M, Vogel AB et al (2012) Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 30(12):1210–1216
-
(2012)
Nat Biotechnol
, vol.30
, Issue.12
, pp. 1210-1216
-
-
Petsch, B.1
Schnee, M.2
Vogel, A.B.3
-
28
-
-
84865994357
-
Nonviral delivery of self-amplifying RNA vaccines
-
Geall AJ, Verma A, Otten GR et al (2012) Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A 109(36): 14604–14609
-
(2012)
Proc Natl Acad Sci U S A
, vol.109
, Issue.36
, pp. 14604-14609
-
-
Geall, A.J.1
Verma, A.2
Otten, G.R.3
-
29
-
-
84927176976
-
A cationic nanoemulsion for the delivery of next-generation RNA vaccines
-
Brito LA, Chan M, Shaw CA et al (2014) A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol Ther. doi:10.1038/mt.2014.133
-
(2014)
Mol Ther
-
-
Brito, L.A.1
Chan, M.2
Shaw, C.A.3
-
30
-
-
84930673065
-
Business: The billion-dollar biotech
-
Dolgin E (2015) Business: The billion-dollar biotech. Nature 522:26–28. doi:10.1038/522026a
-
(2015)
Nature
, vol.522
, pp. 26-28
-
-
Dolgin, E.1
-
32
-
-
85007210773
-
-
Vol. 29, No. 2, 2015 - Proposed International Nonproprietary Names, List 113, Accessed 29 Mar 2016
-
WHO Drug Information Vol. 29, No. 2, 2015 - Proposed International Nonproprietary Names, List 113. http://apps.who.int/medicinedocs/en/m/abstract/Js22000en/. Accessed 29 Mar 2016
-
-
-
-
33
-
-
34548431318
-
Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: Implication for therapeutic RNA development
-
Karikó K, Weissman D (2007) Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development. Curr Opin Drug Discov Devel 10(5):523–532
-
(2007)
Curr Opin Drug Discov Devel
, vol.10
, Issue.5
, pp. 523-532
-
-
Karikó, K.1
Weissman, D.2
-
36
-
-
84862015339
-
RNA-based vaccines
-
Ulmer JB, Mason PW, Geall A, Mandl CW (2012) RNA-based vaccines. Vaccine 30(30):4414–4418
-
(2012)
Vaccine
, vol.30
, Issue.30
, pp. 4414-4418
-
-
Ulmer, J.B.1
Mason, P.W.2
Geall, A.3
Mandl, C.W.4
-
37
-
-
84863549346
-
Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity
-
Uematsu Y, Vajdy M, Lian Y et al (2012) Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity. Clin Vaccine Immunol 19:991–998. doi:10.1128/CVI.00031-12
-
(2012)
Clin Vaccine Immunol
, vol.19
, pp. 991-998
-
-
Uematsu, Y.1
Vajdy, M.2
Lian, Y.3
-
38
-
-
85007249243
-
-
Humana Press, Totowa, NJ
-
Nielsen H (2011) RNA. Humana Press, Totowa, NJ
-
(2011)
RNA
-
-
Nielsen, H.1
-
39
-
-
84908671756
-
Translation of genomics-guided RNAbased personalised cancer vaccines: Towards the bedside
-
Boisguérin V, Castle JC, Loewer M et al (2014) Translation of genomics-guided RNAbased personalised cancer vaccines: towards the bedside. Br J Cancer 111:1469–1475. doi:10.1038/bjc.2013.820
-
(2014)
Br J Cancer
, vol.111
, pp. 1469-1475
-
-
Boisguérin, V.1
Castle, J.C.2
Loewer, M.3
-
40
-
-
84862855875
-
Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination
-
Desmet CJ, Ishii KJ (2012) Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat Rev Immunol 12(7):479–491
-
(2012)
Nat Rev Immunol
, vol.12
, Issue.7
, pp. 479-491
-
-
Desmet, C.J.1
Ishii, K.J.2
-
41
-
-
21044440406
-
Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA
-
Scheel B, Teufel R, Probst J et al (2005) Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. Eur J Immunol 35:1557– 1566. doi:10.1002/eji.200425656
-
(2005)
Eur J Immunol 35:1557–
, pp. 1566
-
-
Scheel, B.1
Teufel, R.2
Probst, J.3
-
42
-
-
77953931139
-
Particle size and activation threshold: A new dimension of danger signaling
-
Rettig L, Haen SP, Bittermann AG et al (2010) Particle size and activation threshold: a new dimension of danger signaling. Blood 115(22):4533–4541
-
(2010)
Blood
, vol.115
, Issue.22
, pp. 4533-4541
-
-
Rettig, L.1
Haen, S.P.2
Bittermann, A.G.3
-
43
-
-
78650640612
-
Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity
-
Fotin-Mleczek M, Duchardt KM, Lorenz C et al (2011) Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother 34(1):1–15
-
(2011)
J Immunother
, vol.34
, Issue.1
, pp. 1-15
-
-
Fotin-Mleczek, M.1
Duchardt, K.M.2
Lorenz, C.3
-
45
-
-
84896958063
-
Innate immune sensing and signaling of cytosolic nucleic acids
-
Wu J, Chen ZJ (2014) Innate immune sensing and signaling of cytosolic nucleic acids. Annu Rev Immunol 32:461–488. doi:10.1146/annurev-immunol-032713-120156
-
(2014)
Annu Rev Immunol
, vol.32
, pp. 461-488
-
-
Wu, J.1
Chen, Z.J.2
-
46
-
-
84924794747
-
Emerging principles governing signal transduction by pattern-recognition receptors
-
Kagan JC, Barton GM (2015) Emerging principles governing signal transduction by pattern-recognition receptors. Cold Spring Harb Perspect Biol 7:a016253. doi:10.1101/cshperspect.a016253
-
(2015)
Cold Spring Harb Perspect Biol
, vol.7
-
-
Kagan, J.C.1
Barton, G.M.2
-
47
-
-
84889654582
-
Nucleic acids and endosomal pattern recognition: How to tell friend from foe?
-
Brencicova E, Diebold SS (2013) Nucleic acids and endosomal pattern recognition: how to tell friend from foe? Front Cell Infect Microbiol 3:37. doi:10.3389/fcimb.2013.00037
-
(2013)
Front Cell Infect Microbiol
, vol.3
, pp. 37
-
-
Brencicova, E.1
Diebold, S.S.2
-
48
-
-
48549097394
-
Accessing the therapeutic potential of immunostimulatory nucleic acids
-
Barchet W, Wimmenauer V, Schlee M, Hartmann G (2008) Accessing the therapeutic potential of immunostimulatory nucleic acids. Curr Opin Immunol 20(4):389–395
-
(2008)
Curr Opin Immunol
, vol.20
, Issue.4
, pp. 389-395
-
-
Barchet, W.1
Wimmenauer, V.2
Schlee, M.3
Hartmann, G.4
-
49
-
-
84859417996
-
Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy
-
Van Lint S, Goyvaerts C, Maenhout S et al (2012) Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res 72(7):1661–1671
-
(2012)
Cancer Res
, vol.72
, Issue.7
, pp. 1661-1671
-
-
Van Lint, S.1
Goyvaerts, C.2
Maenhout, S.3
-
50
-
-
84951802073
-
In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf
-
Hammerich L, Binder A, Brody JD (2015) In situ vaccination: cancer immunotherapy both personalized and off-the-shelf. Mol Oncol 9:1966–1981. doi:10.1016/j. molonc.2015.10.016
-
(2015)
Mol Oncol
, vol.9
, pp. 1966-1981
-
-
Hammerich, L.1
Binder, A.2
Brody, J.D.3
-
51
-
-
84901502933
-
Chapter two - therapeutic cancer vaccines
-
Tew KD, Fisher PB (eds), Academic, New York
-
Schlom J, Hodge JW, Palena C et al (2014) Chapter two - therapeutic cancer vaccines. In: Tew KD, Fisher PB (eds) Advances in cancer research. Academic, New York, pp 67–124
-
(2014)
Advances in Cancer Research
, pp. 67-124
-
-
Schlom, J.1
Hodge, J.W.2
Palena, C.3
-
52
-
-
84921411206
-
RNA-based viral vectors
-
Mogler MA, Kamrud KI (2015) RNA-based viral vectors. Expert Rev Vaccines 14:283–312. doi:10.1586/14760584.2015.979798
-
(2015)
Expert Rev Vaccines
, vol.14
, pp. 283-312
-
-
Mogler, M.A.1
Kamrud, K.I.2
-
53
-
-
84904644314
-
Oncolytic viruses and their application to cancer immunotherapy
-
Chiocca EA, Rabkin SD (2014) Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res 2:295–300. doi:10.1158/2326-6066.CIR-14-0015
-
(2014)
Cancer Immunol Res
, vol.2
, pp. 295-300
-
-
Chiocca, E.A.1
Rabkin, S.D.2
-
54
-
-
78049288264
-
Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns
-
Bachmann MF, Jennings GT (2010) Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 10(11):787–796
-
(2010)
Nat Rev Immunol
, vol.10
, Issue.11
, pp. 787-796
-
-
Bachmann, M.F.1
Jennings, G.T.2
-
55
-
-
84903649476
-
Messenger RNA (MRNA) nanoparticle tumour vaccination
-
Phua KKL, Nair SK, Leong KW (2014) Messenger RNA (mRNA) nanoparticle tumour vaccination. Nanoscale 6:7715–7729. doi:10.1039/c4nr01346h
-
(2014)
Nanoscale
, vol.6
, pp. 7715-7729
-
-
Phua, K.1
Nair, S.K.2
Leong, K.W.3
-
56
-
-
78549283854
-
Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity
-
Kreiter S, Selmi A, Diken M et al (2010) Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 70(22):9031–9040
-
(2010)
Cancer Res
, vol.70
, Issue.22
, pp. 9031-9040
-
-
Kreiter, S.1
Selmi, A.2
Diken, M.3
-
58
-
-
84974712289
-
Thermostable subunit vaccines for pulmonary delivery: How close are we?
-
Foged C (2016) Thermostable subunit vaccines for pulmonary delivery: how close are we? Curr Pharm Des 22(17):2561–2576
-
(2016)
Curr Pharm Des
, vol.22
, Issue.17
, pp. 2561-2576
-
-
Foged, C.1
-
59
-
-
84861186775
-
HIV-1 mRNA electroporation of PBMC: A simple and efficient method to monitor T-cell responses against autologous HIV-1 in HIV-1-infected patients
-
Etschel JK, Hückelhoven AG, Hofmann C et al (2012) HIV-1 mRNA electroporation of PBMC: a simple and efficient method to monitor T-cell responses against autologous HIV-1 in HIV-1-infected patients. J Immunol Methods 380:40–55. doi:10.1016/j.jim.2012.03.005
-
(2012)
J Immunol Methods
, vol.380
, pp. 40-55
-
-
Etschel, J.K.1
Hückelhoven, A.G.2
Hofmann, C.3
-
60
-
-
77949918477
-
Efficient mRNA electroporation of peripheral blood mononuclear cells to detect memory T cell responses for immunomonitoring purposes
-
Van Camp K, Cools N, Stein B et al (2010) Efficient mRNA electroporation of peripheral blood mononuclear cells to detect memory T cell responses for immunomonitoring purposes. J Immunol Methods 354:1–10. doi:10.1016/j.jim.2010.01.009
-
(2010)
J Immunol Methods
, vol.354
, pp. 1-10
-
-
Van Camp, K.1
Cools, N.2
Stein, B.3
-
61
-
-
84878641684
-
Berneman Z (2013) mRNA electroporation as a tool for immunomonitoring
-
Cools N, Van Camp K, Van Tendeloo V, Berneman Z (2013) mRNA electroporation as a tool for immunomonitoring. Methods Mol Biol 969:293–303
-
Methods Mol Biol
, vol.969
, pp. 293-303
-
-
Cools, N.1
Van Camp, K.2
Van Tendeloo, V.3
-
62
-
-
84940970806
-
Anti-infective vaccination in the 21st century — new horizons for personal and public health
-
Scully IL, Swanson K, Green L et al (2015) Anti-infective vaccination in the 21st century — new horizons for personal and public health. Curr Opin Microbiol 27:96–102. doi:10.1016/j.mib.2015.07.006
-
(2015)
Curr Opin Microbiol
, vol.27
, pp. 96-102
-
-
Scully, I.L.1
Swanson, K.2
Green, L.3
-
63
-
-
84924931797
-
The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines
-
Lopalco PL, DeStefano F (2015) The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines. Vaccine 33:1541–1548. doi:10.1016/j.vaccine.2014.10.047
-
(2015)
Vaccine
, vol.33
, pp. 1541-1548
-
-
Lopalco, P.L.1
Destefano, F.2
-
64
-
-
77956656512
-
First-in-human clinical trials with vaccines— what regulators want
-
Goetz KB, Pfleiderer M, Schneider CK (2010) First-in-human clinical trials with vaccines— what regulators want. Nat Biotechnol 28:910–916. doi:10.1038/nbt0910-910
-
(2010)
Nat Biotechnol
, vol.28
, pp. 910-916
-
-
Goetz, K.B.1
Pfleiderer, M.2
Schneider, C.K.3
-
66
-
-
84855383397
-
Intradermal electroporation of naked replicon RNA elicits strong immune responses
-
Johansson DX, Ljungberg K, Kakoulidou M, Liljeström P (2012) Intradermal electroporation of naked replicon RNA elicits strong immune responses. PLoS One 7:e29732. doi:10.1371/journal.pone.0029732
-
(2012)
Plos One
, pp. 7
-
-
Johansson, D.X.1
Ljungberg, K.2
Kakoulidou, M.3
Liljeström, P.4
-
67
-
-
84901269661
-
Enhanced delivery and potency of self-amplifying mRNA vaccines by electroporation in situ
-
Cu Y, Broderick KE, Banerjee K et al (2013) Enhanced delivery and potency of self-amplifying mRNA vaccines by electroporation in situ. Vaccines 1:367–383. doi:10.3390/vaccines1030367
-
(2013)
Vaccines
, vol.1
, pp. 367-383
-
-
Cu, Y.1
Broderick, K.E.2
Banerjee, K.3
-
68
-
-
84921405665
-
Electroporation-enhanced delivery of nucleic acid vaccines
-
Broderick KE, Humeau LM (2015) Electroporation-enhanced delivery of nucleic acid vaccines. Expert Rev Vaccines 14(2):195–204. doi:10.1586/14760584.2015.990890
-
(2015)
Expert Rev Vaccines
, vol.14
, Issue.2
, pp. 195-204
-
-
Broderick, K.E.1
Humeau, L.M.2
-
69
-
-
84885659334
-
The regulatory landscape for actively personalized cancer immunotherapies
-
Britten CM, Singh-Jasuja H, Flamion B et al (2013) The regulatory landscape for actively personalized cancer immunotherapies. Nat Biotechnol 31:880–882. doi: 10.1038/nbt.2708
-
(2013)
Nat Biotechnol
, vol.31
, pp. 880-882
-
-
Britten, C.M.1
Singh-Jasuja, H.2
Flamion, B.3
|